Adelax Tablet: Each coated tablet contains Flupentixol 0.5mg as Dihydrochloride BP and Melitracen 10mg as Hydrochloride INN.
Adelax is a combination preparation of two well known and time tested molecules: Flupentixol-a neuroleptic with anxiolytic and antidepressant properties of its own when given in small doses and Melitracen-a bipolar thymoleptic with activating properties in low doses. In combination, the compounds exert antidepressant, anxiolytic and activating properties. Maximum serum concentration is reached in about 4 hours after oral administration of both Flupentixol and Melitracen. The biological half-life of Flupentixol is about 35 hours and that of Melitracen is about 19 hours. The combination of Flupentixol and Melitracen does not seem to influence the pharma-cokinetic properties of the individual compounds.
Route: Oral
Adults:
Usually 2 tablets daily (morning and noon). In severe cases, morning dose may be increased to 2 tablets. Maintenance: 1 tablet in the morning.
Elderly:
1 tablet in the morning.
MAO inhibitors risk serotonin syndrome and severe hypertensive crisis (allow 14-day washout); potentiates sedative effects of alcohol, barbiturates, and CNS depressants; anticholinergics increase antimuscarinic effects; sympathomimetics potentiate cardiovascular effects.
The immediate recovery phase after myocardial infarction. Defects in bundle-branch conduction. Untreated narrow angle glaucoma. Acute alcohol, barbiturate and opiate intoxications. Flupentixol-melitracen combination should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.
Less Common: Restlessness, insomnia, hypomania. Rare: Dizziness, tremor, visual disturbances, headache, hyperprolactinemia, extrapyramidal symptoms.
Overdose
Symptoms : In case of overdosage the symptoms of intoxications by Melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal symptoms due to Flupentixol occur. Treatment : Symptomatic and supportive. Gastric lavage should be carried out as soon as possible and activated charcoal may be administered. Measures aimed at supporting the respiratory and cardiovascular systems should be instituted. Epinephrine (adrenaline) must not be used for such patients. Convulsions may be treated with diazepam and extrapyramidal symptoms with biperiden.
Category C. Flupentixol-Melitracen combination should not be administered during pregnancy unless benefits clearly outweigh risks. Lactation: Excreted in breast milk; breastfeeding is not recommended.
Store below 30°C in a cool, dry place. Protect from light and moisture. Keep out of reach of children.